Aclarion surges ~30% after cost-effectiveness data presentation for Nociscan software
luza studios/E+ via Getty Images
- Aclarion (NASDAQ:ACON) stock rose ~30% on Thursday after the company said it presented cost-effectiveness abstract for its software Nociscan at the International Society for the Advancement of Spine Surgery on June 3.
- The company noted that the Nociscan cost-effectiveness abstract highlighted dominance over provocative discography (PD) and can save the U.S. healthcare system $283M to $441M annually.
- The cost-effectiveness study evaluating Nociscan to PD was carried out at the Center for Disruptive Musculoskeletal Innovations (CDMI) through a National Science Foundation (NSF) grant sponsored by Aclarion.
- The company added that the study suggests that Nociscan statistically dominates PD because PD is more costly and less effective.
- "We believe the results illustrating Nociscan’s outperformance over provocative discography will be important to our physician customers and their patients, but will also speak clearly to the payer community, who are constantly challenged to reconcile the health outcomes achieved for the dollars they spend," said Aclarion's Chief Strategy Officer Ryan Bond.
- In April, the company reported publication of two-year durability data showing improved surgical outcomes for discogenic low back pain surgeries at painful lumbar discs identified by the Nociscan software.